Acta Crystallographica Section D Biological Crystallography · 2005 · 49 citations · 26 references
Life SciencesBiochemistryMolecular BiologyDrug DesignEnzymologyStructural BiologyEnzyme FunctionEnzyme InhibitionEnzyme StructureProtein StructureStructural EnzymologyStructure-function RelationshipsComparative Enzyme StructureComparative Structural AnalysisCrystal Structure PredictionCrystal Structure RefinementEnzyme Structure-function RelationshipsStructural Comparative AnalysisStructure-based Enzyme DesignTrypanosomatid-host Interactions
The crystal structure of human liver glyceraldehyde-3-phosphate dehydrogenase (GAPDH) has been determined. This structure represents the first moderate-resolution (2.5 A) and crystallographically refined (Rfree = 22.9%) human GAPDH structure. The liver GAPDH structure consists of a homotetramer, each subunit of which is bound to a nicotinamide adenine dinucleotide (NAD+) molecule. The GAPDH enzyme has glycolytic and non-glycolytic functions, both of which are of chemotherapeutic interest. The availability of a high-quality human GAPDH structure is a necessity for structure-based drug design. In this study, structural differences between human liver and skeletal muscle GAPDHs are reported in order to understand how these two enzymes might respond to anti-trypanosomatid GAPDH inhibitors.
26
T. Alwyn Jones, Jin-yu Zou, Sandra W. Cowan et al. · Acta Crystallographica Section A Foundations of Crystallography · 1991 · 12.7K citations
The effect of deprenyl and levodopa on the progression of Parkinson's disease
C. Warren Olanow, Robert A. Hauser, L. Gauguster et al. · Annals of Neurology · 1995 · 335 citations